In vitro and in vivo experimental models for drug screening and development for Chagas disease

dc.creatorRomanha, Álvaro José
dc.creatorCastro, Solange Lisboa de
dc.creatorSoeiro, Maria de Nazaré Correia
dc.creatorVieira, Joseli Lannes
dc.creatorRibeiro, Isabela
dc.creatorTalvani, André
dc.creatorBourdin, Bernadette
dc.creatorBlum, Bethania
dc.creatorOlivieri, Bianca
dc.creatorZani, Carlos Leomar
dc.creatorSpadafora, Carmenza
dc.creatorChiari, Égler
dc.creatorChatelain, Eric
dc.creatorChaves, Gabriela
dc.creatorCalzada, José Eduardo
dc.creatorBustamante, Juan Manuel
dc.creatorFreitas Junior, Lucio Holanda Gondim de
dc.creatorRomero, Luz I.
dc.creatorBahia, Maria Terezinha
dc.creatorLotrowska, Michel
dc.creatorSoares, Milena Botelho Pereira
dc.creatorAndrade, Sonia Gumes
dc.creatorArmstrong, Tanya
dc.creatorDegrave, Wim
dc.creatorAndrade, Zilton de Araújo
dc.date2012-11-12T19:20:36Z
dc.date2012
dc.date2010
dc.date.accessioned2023-09-27T00:12:12Z
dc.date.available2023-09-27T00:12:12Z
dc.identifierROMANHA, Alvaro et al. In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 105(2): 233-238, March 2010
dc.identifier0074-0276
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/5794
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8898479
dc.descriptionFiocruz, DNDi
dc.descriptionChagas disease, a neglected illness, affects nearly 12-14 million people in endemic areas of Latin America. Al¬though the occurrence of acute cases sharply has declined due to Southern Cone Initiative efforts to control vector transmission, there still remain serious challenges, including the maintenance of sustainable public policies for Chagas disease control and the urgent need for better drugs to treat chagasic patients. Since the introduction of benznidazole and nifurtimox approximately 40 years ago, many natural and synthetic compounds have been as¬sayed against Trypanosoma cruzi, yet only a few compounds have advanced to clinical trials. This reflects, at least in part, the lack of consensus regarding appropriate in vitro and in vivo screening protocols as well as the lack of biomarkers for treating parasitaemia. The development of more effective drugs requires (i) the identification and validation of parasite targets, (ii) compounds to be screened against the targets or the whole parasite and (iii) a panel of minimum standardised procedures to advance leading compounds to clinical trials. This third aim was the topic of the workshop entitled Experimental Models in Drug Screening and Development for Chagas Disease, held in Rio de Janeiro, Brazil, on the 25th and 26th of November 2008 by the Fiocruz Program for Research and Technological Development on Chagas Disease and Drugs for Neglected Diseases Initiative. During the meeting, the minimum steps, requirements and decision gates for the determination of the efficacy of novel drugs for T. cruzi control were evaluated by interdisciplinary experts and an in vitro and in vivo flowchart was designed to serve as a general and standardised protocol for screening potential drugs for the treatment of Chagas disease.
dc.formatapplication/pdf
dc.languageeng
dc.publisherInstituto Oswaldo Cruz
dc.rightsopen access
dc.subjectTrypanosoma cruzi
dc.subjectChagas disease treatment
dc.subjectdrug screening
dc.subjectbenznidazole
dc.titleIn vitro and in vivo experimental models for drug screening and development for Chagas disease
dc.typeArticle


Este ítem pertenece a la siguiente institución